Period:
Draw Mode:
| Volume | 7,252 |
|
|||||
| News | - | ||||||
| Day High | 2.33 | Low High |
|||||
| Day Low | 2.26 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Spruce Biosciences Inc | SPRB | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.03 | 1.32% | 2.30 | 14:05:04 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.31 | 2.26 | 2.33 | 2.27 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 87 | 7,252 | $ 2.30 | $ 16,711 | - | 0.9547 - 3.57 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 14:05:12 | 58 | $ 2.25 | USD |
Spruce Biosciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 93.63M | 40.71M | - | 0 | -46.18M | -1.13 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Spruce Biosciences News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SPRB Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.43 | 2.51 | 2.25 | 2.36 | 28,001 | -0.13 | -5.35% |
| 1 Month | 2.25 | 2.75 | 2.1425 | 2.44 | 119,680 | 0.05 | 2.22% |
| 3 Months | 2.12 | 2.75 | 2.00 | 2.34 | 73,629 | 0.18 | 8.49% |
| 6 Months | 2.26 | 2.75 | 1.90 | 2.29 | 118,952 | 0.04 | 1.77% |
| 1 Year | 1.37 | 3.57 | 0.9547 | 2.36 | 453,278 | 0.93 | 67.88% |
| 3 Years | 17.00 | 35.60 | 0.9547 | 4.26 | 537,980 | -14.70 | -86.47% |
| 5 Years | 17.00 | 35.60 | 0.9547 | 4.26 | 537,980 | -14.70 | -86.47% |
Spruce Biosciences Description
| Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH). |